Viking Therapeutics
VKTX | NASDAQ
$26.80
-$2.42 (-8.28%)
At close: Nov 16, 2026, 4:00 PM ET
$26.73
-$0.07 (-0.26%)
After-hours:
Nov 16, 2026, 7:57 PM ET
Viking Therapeutics Company Profile
Company profile explainedCompany Profile
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Brian Lian | President, Chief Executive Officer & Director |
| Gregory S. Zante | Chief Financial Officer |
| Geoffrey E. Barker | Chief Development Officer |
| Hubert C. Chen | Chief Medical Officer |
| Katherine Mercier | Vice President of Quality and Compliance |
| Kenneth Herman | Senior Vice President of Commercial, Marketing & Sales |
| Michael Morneau | Vice President of Finance & Administration |
| Neil Aubuchon | Chief Commercial Officer |
| Nils U. Olsson | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 10-Q | Quarterly Report |
| Oct 28, 2026 | 8-K | Current Report |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 25, 2026 | 424B5 | Filing |
| Sep 25, 2026 | 424B5 | Filing |
| Sep 24, 2026 | FWP | Filing |
| Sep 24, 2026 | 305B2 | Filing |
| Sep 23, 2026 | 424B5 | Filing |
| Sep 23, 2026 | 424B5 | Filing |
| Sep 22, 2026 | 8-K | Current Report |
Viking Therapeutics
| Country | United States |
| IPO Date | Apr 28, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 53 |
| CEO | Brian Lian |
Contact Details
9920 Pacific Heights Boulevard San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | VKTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001607678 |
| CUSIP Number | 92686J106 |
| ISIN Number | US92686J1060 |
| SIC Code | 2834 |
Recent News
- 1 day ago / gurufocus.comViking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
- 3 days ago / fool.comPrediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
- 5 days ago / fxempire.comViking Therapeutics (VKTX) Price Forecast: Bullish Reversal Targets $43.55
- 8 days ago / prnewswire.comViking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
- 12 days ago / fool.comHere's the 1 Stock I'd Most Want to Buy If the Market Crashes
- 13 days ago / fool.comViking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.
- 13 days ago / prnewswire.comViking Therapeutics to Participate at Upcoming Investor Conferences
- 18 days ago / zacks.comVKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
- 18 days ago / zacks.comBrokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
- 19 days ago / zacks.comVKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses
Add to Watchlist
Select watchlists to add or remove VKTX